Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Oncology clinicians are using an increasing number of tumor next-generation sequencing (NGS) tests to help determine treatment options for patients with cancer, including for use of standard-of-care targeted therapies, enrollment on clinical trials, and use of off-label treatments. With increased testing and the growing size of panels, more variants are being uncovered.
Approximately 40% of cancer-related clinical trials terminate prematurely,1 which results in an immense loss of time, money, and human effort. Failure to optimize clinical trial design, inefficient enrollment processes, and poor accrual rates are the main reasons for premature trial closure.1 As successful trial accrual is paramount to drug discovery, efforts to address this challenge are urgently needed.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
